Beyond the knife: strategic patient selection for cytoreductive nephrectomy

S Brönimann, Y Ged, N Singla - Current opinion in urology, 2024 - journals.lww.com
The role and timing of CN in mRCC have evolved across therapeutic eras. Although
awaiting prospective evidence in the current era of ICI, CN still has a role in the therapeutic …

Controlling nutritional status score before receiving treatment as a prognostic indicator for patients with urothelial cancer: an exploration evaluation methods

L Peng, C Du, C Meng, J Li, C You, X Li, P Zhao… - Frontiers in …, 2021 - frontiersin.org
Introduction This meta-analysis aims to assess whether the Controlling nutritional status
(CONUT) score before treatment can be an independent predictor of the prognosis of …

Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: analysis of a Japanese nationwide cohort

K Ito, T Kobayashi, T Kojima, K Hikami… - Cancer …, 2021 - Wiley Online Library
Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma
(UC) and impaired performance status (PS) remain unknown. This study assessed the safety …

[HTML][HTML] Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

JT Brown, Y Liu, JM Shabto, D Martini… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background The modified Glasgow Prognostic Score (mGPS) is a composite biomarker that
uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor …

The Elderly Functional Index (ELFI), a patient-reported outcome measure of functional status in patients with cancer: a multicentre, prospective validation study

WK Soo, M King, A Pope, C Steer, B Devitt… - The Lancet Healthy …, 2021 - thelancet.com
Background Functional assessment of patients with cancer can be challenging and is often
undertaken by the clinician with minimal direct input from the patient. We developed and …

Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment

L Guo, Y Su, X Liu, W Xie, S Meng, Y Liu… - Oncology …, 2023 - spandidos-publications.com
Abstract Cell division cycle 42 (CDC42) regulates immune escape, which predicts immune
checkpoint inhibitor (ICI) treatment response in several types of cancer. The present study …

Students and physicians differ in perception of quality of life in patients with tumors of the upper gastrointestinal tract

L Schooren, G Oberhoff, S Schipper, A Koch, A Kroh… - Scientific Reports, 2024 - nature.com
Health-related quality of life (HRQoL) has recently gained importance as treatment options
for tumors of the upper GI tract lead to improved long-term survival. HRQoL is often …

[HTML][HTML] External validation and diagnostic value of the Elderly Functional Index version 2.0 for assessing functional status and frailty in older Danish patients with …

E Jespersen, WK Soo, LR Minet, HR Eshoj… - Journal of Geriatric …, 2024 - Elsevier
Introduction Patient perspectives on functioning are often overlooked in oncology practice.
This study externally validates the ELderly Functional Index (ELFI), a patient-reported …

[PDF][PDF] The Value of Alleviating Serious Health-Related Suffering and Palliative Care Based on Lived Experience: Development of the SAVE Study Protocol

A Bhadelia, N Greaves, S Doubova, F Knaul - 2024 - assets-eu.researchsquare.com
Health-related suffering generated by life-limiting or life-threatening conditions is a complex
phenomenon inextricably linked with human experience. Most of this suffering can be …

Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone …

II Nnabugwu, EN Obikeze, CA Nnabugwu… - Health and Quality of …, 2024 - Springer
Background Performance status and health-related quality of life (HRQoL) are important
parameters in the management of metastatic prostate cancer. The clinician-rated Eastern …